Loading...
Market
What will be Colossal Biosciences' next de-extinction target by end of 2025?
2
Resolution / Starting Odds
Passenger Pigeon • 25%
Saber-toothed Tiger • 25%
Moa • 25%
Other • 25%
Official announcements from Colossal Biosciences
Story
Colossal Biosciences Raises $200M, Valued at $10.2B to Revive Woolly Mammoth, Dodo, and Tasmanian Tiger
Jan 15, 2025, 09:15 PM
Colossal Biosciences, a Dallas-based startup focused on de-extinction, has raised $200 million in a Series C funding round, bringing its valuation to $10.2 billion. The company, which aims to revive extinct species such as the woolly mammoth, dodo, and Tasmanian tiger, has now secured a total of $435 million in funding since its inception in 2021. The latest round was led by TWG Global, with Mark Walter and Thomas Tull at the helm. Colossal plans to use the new funds to expand its team, develop new technologies, and broaden its list of species targeted for de-extinction.
View original story
Similar markets
Other • 25%
Woolly Mammoth • 25%
Tasmanian Tiger • 25%
Dodo Bird • 25%
Yes • 50%
No • 50%
Woolly Mammoth • 25%
Dodo Bird • 25%
Thylacine • 25%
Other • 25%
2 new species • 25%
3 new species • 25%
1 new species • 25%
More than 3 new species • 25%
WWF • 25%
Conservation International • 25%
The Nature Conservancy • 25%
Other • 25%
Gene affecting fur color in dogs • 25%
No related discoveries • 25%
Gene affecting skin color in reptiles • 25%
Gene affecting fur color in rabbits • 25%
Other known species • 25%
Newly identified species • 25%
Megalosaurus • 25%
Cetiosaurus • 25%
Below $5B • 25%
Above $15B • 25%
$10.2B to $15B • 25%
$5B to $10.2B • 25%
